FcγRIIB Genotyping for ITP Treatment Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for idiopathic thrombocytopenic purpura (ITP) do not effectively predict therapeutic responses to Fc gamma receptor IIB (FcγRIIB) therapy, leading to uncertainty in patient susceptibility and response to therapies like SM101.
Innovation Solution
The allelic pattern for FcγRIIB, specifically the homozygous FcγRIIB 232 I/I genotype, is identified as a predictive marker for a positive therapeutic response, allowing for personalized treatment strategies and stratification of patients for FcγRIIB therapy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments (steroids, Anti-D, thrombopoietin receptor agonists) are used for ITP patients, then platelet count can be improved, but therapeutic response cannot be predicted and treatment cost increases
Solution Approach 1:
The patent applies preliminary action by determining the FcγRIIB genotype (specifically the 232 I/I homozygous genotype) before initiating FcγRIIB therapy. This genetic screening allows clinicians to predict which patients will respond positively to FcγRIIB therapy, enabling treatment decisions to be made in advance based on genetic information rather than trial-and-error approaches.
Solution Approach 2:
The patent utilizes parameter changes by focusing on the genetic parameter (FcγRIIB genotype) as a predictive marker. By measuring this specific genetic parameter, the patent transforms the ability to predict therapeutic response from uncertain to predictable, allowing stratification of patients based on their genetic profile and expected treatment outcome.
2Ease of operation
If FcγRIIB therapy is administered without genotype screening, then treatment access is improved, but resource waste occurs due to non-responders
Solution Approach 1:
The patent performs genotype determination as a preliminary step before administering FcγRIIB therapy. This advance screening identifies patients with the 232 I/I genotype who are likely to respond, allowing resources to be directed efficiently to those most likely to benefit while preventing waste on non-responders.
Solution Approach 2:
The patent applies local quality by tailoring treatment allocation based on individual patient characteristics (genotype). Instead of uniform treatment distribution, the patent enables targeted therapy delivery to specific patient subgroups (232 I/I homozygotes) who have the local quality of being genetically predisposed to respond to FcγRIIB therapy.
3Measurement precision
If personalized treatment strategies are implemented based on FcγRIIB genotype, then treatment precision is improved, but diagnostic complexity increases
Solution Approach 1:
The patent focuses on measuring a specific genetic parameter (FcγRIIB genotype at position 232) to achieve precise patient stratification. By concentrating on this single polymorphic site rather than comprehensive genomic analysis, the patent maintains measurement precision while minimizing diagnostic complexity.
Solution Approach 2:
The patent applies segmentation by dividing the patient population into distinct subgroups based on FcγRIIB genotype (specifically identifying 232 I/I homozygotes). This segmentation enables precise targeting of FcγRIIB therapy to the relevant subgroup without requiring complex multi-parameter assessments of all patients.
Data Source
AI summary
The present invention provides for a method for excluding a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject comprising determining as to whether at least one autoantibody or antigen which is indicative for at least one rheumatic disorder is present in a sample obtained from the subject, wherein the presence of said autoantibody or antigen allows to exclude a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject. Accordingly, it provides for a method that triggers the next steps in diagnosing the cause of a musculoskeletal complaint of a subject - either further diagnosis of a rheumatic disorder or of a non-rheumatic disorder to confirm the initial diagnosis. Also provided is a kit for excluding a non-rheumatic disorder as cause of a musculoskeletal complaint of a subject as well as uses of the kit.